Open an account

Qiagen NV

QGEN · NYSE

$48.90+$2.35 (+5.05%)TodayMarket closed ·
Prev close $46.55

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees
5,654
Headquarters
Venlo, Limburg
Listed
Sep 1, 1996
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
qiagen.com

QGEN key statistics

Market cap
10.08B
Price-earnings ratio
24.24
Dividend yield
—
Average volume
2.21M
Volume
10.13M
Open price
$46.97
High today
$50.82
Low today
$46.62
52 Week high
$57.82
52 Week low
$32.53

Qiagen NV (QGEN) at a glance

Qiagen NV (QGEN) last traded at $48.90, with a market cap of 10.08B and a price-to-earnings ratio of 24.24.

Today the stock has traded between $46.62 and $50.82. The current price is 4.9% above the day's low and 3.8% below its high.

Volume so far is 10.13M shares, above the average of 2.21M shares a day.

Over the past year Qiagen NV has ranged from $32.53 to $57.82, and now sits 65% of the way up that range.

Qiagen NV met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $0.62 per share against an estimate of $0.6103.

The average analyst price target is $46.77, 4.4% below the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 10 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 18 analystsAvg $46.77
Low
$40.40
Now
$48.90
High
$53.01

QGEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 3.7% on average.

  1. Q3 FY24: reported $0.6171 per share against an estimate of $0.597
  2. Q4 FY24: reported $0.6421 per share against an estimate of $0.6678
  3. Q1 FY25: reported $0.5789 per share against an estimate of $0.5371
  4. Q2 FY25: reported $0.6316 per share against an estimate of $0.6471
  5. Q3 FY25: reported $0.6421 per share against an estimate of $0.6288
  6. Q4 FY25: reported $0.62 per share against an estimate of $0.6394
  7. Q1 FY26: reported $0.54 per share against an estimate of $0.5515
  8. Q2 FY26: reported $0.62 per share against an estimate of $0.6103

QGEN news

  • 'EQT Is in Advanced Talks to Buy Testing Firm Qiagen' - Bloomberg

  • Press releaseBusiness Wire

    QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

  • Press releaseBusiness Wire

    QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

  • Press releaseBusiness Wire

    QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

  • Press releaseBusiness Wire

    QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

  • Press releaseBusiness Wire

    QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

  • Vandana Singh

    Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit

  • Press releasePRNewswire

    10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.